The UK charity for Waldenstrom’s macroglobulinaemia – a rare type of blood cancer
Support Line: 0300 373 8500

Showing only trials that are Scotland

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström’s Macroglobulinemia
Understanding the safety and efficacy of a new drug that stops a certain type of protein working
Expected to end: 01/09/2028
A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)
Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed
Expected to end: 29/01/2027
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Testing a new treatment to understand it’s efficacy and the best dose for patients
Expected to end: 31/03/2028
A Study of NX-5948 in Adults With Relapsed/​Refractory B-cell Malignancies
The first trial in humans for a new type of BTK degrader
Expected to end: 01/01/2028
A study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
An early phase study of the efficacy and safety of a new drug
Expected to end: 08/01/2026
Study to Evaluate CCS1477 in Haematological Malignancies
Finding out more about a new type of targeted treatment
Expected to end: 30/06/2025